References

Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL 1997 Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its p55 receptor. J Clin Invest 100:1557-1565

Akatsu T, Takahashi N, Udagawa N et al 1991 Role of prostaglandins in interleukin-1-induced bone resorption in mice invitro. J Bone Miner Res 6:183-189 Anderson DM, Maraskovsky E, Billingsley WL et al 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179 Arch RH, Gedrich RW, Thompson CB 1998 Tumor necrosis factor receptor-associated factors (TRAFs) — a family of adapter proteins that regulates life and death. Genes Dev 12: 2821-2830

Assuma R, Oates T, Cochran D, Amar S, Graves DT 1998 IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 160:403-409 Bucay N, Sarosi I, Dunstan CR et al 1998 Osteoprotegerin-deficient mice develop early onset of osteoporosis and arterial calcification. Genes Dev 12:1260-1268 Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV 1996 TRAF6 is a signal transducer for interleukin-1. Nature 383:443-446 Chambers TJ, Owens JM., Hattersley G, Jat PS, Noble MD 1993 Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. Proc Natl Acad Sci USA 90:5578-5582 Felix R, Cecchini MG, Fleisch H 1990 Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 127:2592-2594

Jimi E, Akiyama S, Tsurukai T et al 1999a Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434-442

Jimi E, Nakamura I, Duong LT et al 1999b Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247:84-93

Kobayasi K, Takahashi N, Jimi E et al 2000 Tumor necrosis factor a stimulates osteoclast differentiation independent of the ODF/RANK signaling system. J Exp Med 191:275-285 Kong YY, Yoshida H, Sarosi I et al 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323 Lacey DL, Timms E, Tan HL et al 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 Lomaga NIA, Yeh WC, Sarosi I et al 1999 TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015-1024 Matsuzaki K, Udagawa N, Takahashi N et al 1998 Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246:199-204 Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL 1999 Tumor necrosis factor-a mediates orthopedic implant osteolysis. Am J Pathol 154:203-210 Mizuno A, Amizuka N, Irie K et al 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615 Nakagawa N, Kinosaki M, Yamaguchi K et al 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400

Naito A, Azuma S, Tanaka S et al 1999 Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353-362 Simonet WS, Lacey DL, Dunstan CR et al 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319 Suda T, Takahashi N, Martin TJ 1992 Modulation of osteoclast differentiation. Endocr Rev

13:66-80 (erratum: 1992 Endocr Rev 13:191) Suda T, Takahashi N, Martin TJ 1995 Modulation of osteoclast differentiation: update 1995

Endocr Rev Monographs 4:266-270 Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357 Takahashi N, Akatsu T, Udagawa N et al 1988 Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2602 Tartaglia LA, Goeddel DV 1992 Two TNF receptors. Immunol Today 13:151-153 Tsuda E, Goto M, Mochizuki S et al 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142

Udagawa N, Takahashi N, Akatsu T et al 1989 The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in co-cultures with mouse spleen cells. Endocrinology 125:1805-1813 Yasuda H, Shima N, Nakagawa N et al 1998a Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis invitro. Endocrinology 139:1329-1337 Yasuda H, Shima N, Nakagawa N et al 1998b Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602

Yeh WC, Shahinian A, Speiser D et al 1997 Early lethality, functional NF-kB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715— 725

Yoshida H, Hayashi S, Kunisada T et al 1990 The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442—444

Wong BR, Rho J, Arron J et al 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190—25194

Wong BR, Josien R, Choi Y1999 TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65:715—724

Was this article helpful?

0 0

Post a comment